No Data
No Data
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
BMO Capital Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $105
Merck Downgraded by BMO Over Keytruda Concerns
No Data